RegulatoryCompany release

FDA grants Priority Review to Palvella's QTORIN rapamycin NDA for microcystic lymphatic malformations

🇺🇸 Palvella Therapeutics, Inc. (PVLA) · Thu 05 Nov 2026

The US regulator has accepted Palvella's application and set a PDUFA action date of 28 February 2027, with a standalone launch planned for the first half of 2027 if approved.

Palvella Therapeutics has announced that the US Food and Drug Administration has accepted its new drug application for QTORIN rapamycin in microcystic lymphatic malformations and granted it Priority Review. The company disclosed the news on 5 November 2026 alongside its third-quarter 2026 financial results.

The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of 28 February 2027. Priority Review is a designation that aims to shorten the FDA's review timeline compared with a standard review.

Palvella said it is preparing a standalone US launch in the first half of 2027, contingent on approval. The company did not, in the information available, provide further detail on launch plans.

On the financial side, Palvella reported cash of $236.7 million and a net loss of $24.6 million for the third quarter.

What it means for your team

  • Regulatory teams tracking rare-disease filings can add 28 February 2027 to their calendars as the FDA decision date for QTORIN rapamycin.
  • Market-access and commercial planners should note the company's intended standalone US launch in the first half of 2027, subject to approval.
  • Pharmacovigilance and quality groups at the company will face launch-readiness demands if approval is granted, though the company has given no details on this.

Company's press release (SEC filing): Palvella Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Palvella Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →